Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWegovy (semaglutide) is taken once a week, on any day you choose, by subcutaneous injection. That single weekly dose is a fixed part of its licensed schedule: the treatment begins at a low starting dose and is increased gradually by your prescriber over roughly four months until you reach the 2.4 mg maintenance dose — or, for those on the newer 7.2 mg pathway, up to that higher level. Because Wegovy is a prescription-only medicine, a prescriber assesses your suitability before treatment begins and reviews your progress before each repeat; the schedule is guided by clinical judgement, not self-direction.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Semaglutide is engineered with a fatty-acid side chain that binds to albumin in the bloodstream, giving it a half-life of around seven days in the body. That long half-life is the reason a single weekly injection maintains stable drug levels, there are no meaningful peaks and troughs between doses the way there are with shorter-acting medicines taken daily. The NHS explains this pharmacology on its semaglutide medicines page, which is worth bookmarking for reference throughout treatment.
From a practical standpoint, once a week is also easier to stick to. Pick a day (Thursday, say) and it becomes a habit quickly. Some people link it to a weekly routine: the same morning they put a wash on, or before they leave for the gym. One practical habit worth building: set a recurring phone reminder for the night before so you remember to take the pen out of the fridge in good time. That's it. Thirty seconds of preparation.
Because the medicine stays active all week, you get continuous appetite regulation rather than a daily on-off effect. This matters for how Wegovy works in practice, the consistent level in your system is part of what produces the steady reduction in appetite that the clinical trial evidence documents.
The standard pathway runs across approximately 16 to 20 weeks before you reach 2.4 mg. You start at 0.25 mg, a dose that exists purely to ease your digestive system in gently, not to produce meaningful weight loss yet. After four weeks the prescriber moves you to 0.5 mg, then 1.0 mg, then 1.7 mg, and finally 2.4 mg. Each rung lasts roughly a month.
For some people the titration takes longer. If side effects at a particular dose are troublesome, a prescriber may hold you at that level for an extra four weeks before stepping up. That is a clinical call, not a failure. The STEP 1 trial (published in the New England Journal of Medicine and involving nearly 2,000 adults over 68 weeks) used 2.4 mg as the maintenance dose and recorded an average weight reduction of around 15%. That figure comes from a structured, supervised titration; the schedule matters as much as the medicine itself.
Questions about how often you use Wegovy across the whole programme often reflect a reasonable concern: is once a week really enough, or should you be doing more? The answer is genuinely yes, once weekly is both the licensed frequency and the one the evidence is built on.
No. Even at the higher 7.2 mg level, Wegovy remains a once-weekly injection. The frequency never changes, only the amount per injection increases. The MHRA approved 7.2 mg in January 2026, initially administered as three 2.4 mg pens in a single week. On 14 April 2026 a dedicated single-dose 7.2 mg pen was approved, making the process identical to the standard pathway: one injection, once a week. The single-dose pen was designed specifically for BMI ≥30 and is not indicated below that threshold.
Trial data for the 7.2 mg dose reported average weight loss of around 20.7% over 72 weeks, a result that narrows the gap with tirzepatide's highest-dose figures. You can read more about how the two medicines compare on the semaglutide overview. Whether the 7.2 mg pathway is right for you is something our prescribers assess individually; specific dose availability is confirmed at consultation, not assumed in advance.
It is also worth noting that how often semaglutide is taken depends on which formulation you are using. The new Wegovy tablet (oral semaglutide, approved by the MHRA on 11 June 2026) is taken once daily rather than once weekly, the two routes involve different schedules and different escalation ladders entirely.
Life happens. If your usual injection day passes and you remember within five days, take the dose as soon as you can, then return to your normal schedule. If it has been more than five days since the missed dose, skip it and pick up where you would have been the following week. Do not take two doses close together to compensate. The Patient Information Leaflet that comes with your pen sets this out clearly, it is the definitive reference, not any website including this one.
Switching your weekly day is straightforward provided the gap between doses stays at least four days. So if you normally inject on Mondays but want to move to Thursdays, you can do that in a single adjustment, as long as Monday to Thursday is at least four days apart, which it is.
If you are uncertain about anything in your schedule, our support team is available seven days a week. For broader questions about the treatment programme, our FAQs page covers a range of practical queries. And if you are still deciding whether Wegovy suits your situation, a free consultation with our prescribers is the right starting point, they review each case on the same day it arrives, and they can talk you through the full schedule before you commit to anything.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.